BamSEC and AlphaSense Join Forces
Learn More

Calidi Biotherapeutics Inc. – Material Contracts

NYSE American: CLDI    
Share price (8/21/26): $1.34    
Market cap (8/21/26): $3.463 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 8-K 3 pages Lease Termination Agreement
12/34/56
EX-10.1
from 8-K 74 pages Genesis Morehouse at 5580 Lease Bp3-Sd4 5580 Morehouse Drive LLC, a Delaware Limited Liability Company, as Landlord, and Calidi Biotherapeutics, Inc., a Delaware Corporation, as Tenant Summary of Basic Lease Information
12/34/56
EX-10.1
from 8-K 16 pages Warrant Agency Agreement
12/34/56
EX-10.2
from 8-K 12 pages Material Purchase Agreement
12/34/56
EX-10.1
from 8-K 11 pages Stock Repurchase Agreement
12/34/56
EX-10.2
from 8-K 5 pages Consulting Agreement
12/34/56
EX-10.1
from 8-K 8 pages September 16, 2025 To: Wendy Pizarro Re: Confidential Separation Agreement Dear Wendy: This Letter Sets Forth the Terms of the Separation Agreement (The “Agreement”) That Calidi Biotherapeutics, Inc. (The “Company”) Is Offering to Aid in Your Employment Transition. This Agreement Shall Be Effective on the “Effective Date” Specified Herein. 1. Separation. Your Employment With the Company Is Terminated Effective October 17, 2025 (The “Separation Date”)
12/34/56
EX-10.1
from 8-K 8 pages 7/24/2025 To: Boris Minev, MD 4587 Mercurio Street San Diego, Ca 92130 Re: Confidential Separation Agreement Dear Boris: This Letter Sets Forth the Terms of the Separation Agreement (The “Agreement”) That Calidi Biotherapeutics, Inc. (The “Company”) Is Offering to Aid in Your Employment Transition. This Agreement Shall Be Effective on the “Effective Date” Specified Herein. 1. Separation. Your Employment With the Company Is Terminated Effective 7/29/2025 (The “Separation Date”)
12/34/56
EX-10.1
from 8-K 11 pages July 9, 2025 [Name and Address of Holder] Re: Series A, B, C, D, E and F Warrant Exercise Agreement to Whom It May Concern
12/34/56
EX-10.2
from 8-K 24 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 10 pages General Release of Claims and Transition Agreement
12/34/56
EX-10.2
from 8-K 13 pages Placement Agency Agreement March 27, 2025
12/34/56
EX-10.1
from 8-K 32 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 14 pages Placement Agency Agreement
12/34/56
EX-10.1
from 8-K 13 pages Placement Agency Agreement November 14, 2024
12/34/56
EX-10.2
from 8-K 13 pages Placement Agency Agreement October 23, 2024
12/34/56
EX-10.1
from 8-K 32 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 44 pages At the Market Offering Agreement
12/34/56
EX-10.3
from 8-K 4 pages Intellectual Property Assignment Agreement
12/34/56
EX-10.1
from 8-K 10 pages Subscription Agreement
12/34/56